Literature DB >> 16274270

Chemotherapy for malignant glioma.

M Kelly Nicholas1, Rimas Lukas, Samir Bangalore.   

Abstract

Malignant gliomas comprise a small percentage of all cancers, but continue to cause disproportionate levels of morbidity and mortality. Despite decades of intensive effort from many disciplines--surgery, radiation oncology and medicine--they remain refractory to cure and, in most cases, even to prolonged treatment response. Comprehensive multidisciplinary treatment is well recognized as the optimal approach. While continued advances and refinement in both surgical and radiotherapy-based techniques are certain, medical therapies are expanding at a much more rapid rate. This is due, in large part, to an understanding of the molecular events that underlie cancer pathogenesis and improved laboratory techniques to manufacture and study molecules that influence this process. This review will focus on medical therapies in the treatment of malignant glioma, never losing sight of their place as one of several therapeutic modalities used to confront brain cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16274270     DOI: 10.1586/14737175.5.6.S41

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  3 in total

1.  Triptolide inhibits proliferation and invasion of malignant glioma cells.

Authors:  Haipeng Zhang; Wenbo Zhu; Xingwen Su; Sihan Wu; Yuan Lin; Jingjie Li; Youqiong Wang; Jingkao Chen; Yuxi Zhou; Pengxin Qiu; Guangmei Yan; Shujin Zhao; Jun Hu; Jingxia Zhang
Journal:  J Neurooncol       Date:  2012-05-05       Impact factor: 4.130

2.  Targeted anticancer potential against glioma cells of thymoquinone delivered by mesoporous silica core-shell nanoformulations with pH-dependent release.

Authors:  Samar A Shahein; Khaled AbouAitah; Ahmed M Aboul-Enein; Iman M Higazy; Faten Abou-Elella; Witold Lojkowski; Esam R Ahmed; Shaker A Mousa
Journal:  Int J Nanomedicine       Date:  2019-07-19

3.  Imipramine impedes glioma progression by inhibiting YAP as a Hippo pathway independent manner and synergizes with temozolomide.

Authors:  Yan Wang; Xiang Wang; Xu Wang; Di Wu; Ji Qi; Yu Zhang; Kai Wang; Ding Zhou; Qing-Ming Meng; Er Nie; Qiang Wang; Ru-Tong Yu; Xiu-Ping Zhou
Journal:  J Cell Mol Med       Date:  2021-09-01       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.